Skip to content

comparing the effect of meperidine and ondansetron in treatment of post anesthesia shivering

Comparison of ondansetrone and meperedin for treatment of post anaesthesia shivering – A randomized controlled clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201107237093N1
Enrollment
200
Registered
2011-09-11
Start date
2011-08-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post anesthesia shivering. Misadventures to patients during surgical and medical care

Interventions

Intervention 1: Intervention group1: meperedine 4mg/kg=4cc. Intervention 2: Intervention group 2: ondansetron 4mg=4cc. Intervention 3: Control group: normal saline 4 cc.
Treatment - Drugs
Placebo
Intervention group1: meperedine 4mg/kg=4cc
Intervention group 2: ondansetron 4mg=4cc
Control group: normal saline 4 cc

Sponsors

North khorasan University Of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: ASA 1 and 2; age 18-65; uncomplicated surgery and anesthesia; all types of surgery; all types of anesthesia Exclusion criteria: complicated anesthesia and surgery; required blood transfusion; taking drugs in pre-anesthesia period (ondansetron, pethedine); opium based anesthesia; addiction; pre-anesthesia hypothermia (less than36c) or hyperpyrexia (more than 38c); obesity (more than 100kg or BMI more than 35); hypo or hyperthyroidism; parkinson; Reynaud syndrome and diagnosis of dysautonomia; post-operative hypotension more than 20%; known allergy to ondansetron or pethedin; post operative nausea & vomiting; taking benzodiazepines in recovery room

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Post anesthesia shivering. Timepoint: continuously during recovery stay. Method of measurement: Questionnaire.

Secondary

MeasureTime frame
Response to treatment. Timepoint: immediately after injection of drugs. Method of measurement: inspection- questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohsen Sabermoghadam

Imam Ali Hospital

sabermoghadam41@gmail.com+98 58 4224 6739

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026